FDA Approval of Flibanserin — Treating Hypoactive Sexual Desire Disorder

Abstract

After three reviews, the FDA approved flibanserin for hypoactive sexual desire disorder in premenopausal women, concluding that efficacy had been established but requiring a boxed warning, an alcohol contraindication, and a risk evaluation and mitigation strategy.